Author Interviews, Brigham & Women's - Harvard, Cost of Health Care, JAMA / 09.06.2022
Expensive New Drugs Often Provide Little Substantial Benefit Over Existing Medications
MedicalResearch.com Interview with:
Benjamin N. Rome MD
Instructor, Harvard Medical School
Internal Medicine
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women’s Hospital
MedicalResearch.com: What is the background for this study?
What are the main findings?
Response: Manufacturers of brand-name drugs are granted periods, free from direct competition, during which they can set and raise prices as they choose.
We found that the prices for newly marketed brand-name drugs increased by 20% per year from 2008 to 2021. In 2020 and 2021, nearly half of new drugs were launched at a price greater than $150,000 per year, compared with 9% of drugs in 2008-2013. These dramatic trends are only partly explained by changes in the types of drugs coming to market.
(more…)